Acadia Pharmaceuticals
ACAD
248 hedge funds and large institutions have $3.25B invested in Acadia Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 92 increasing their positions, 73 reducing their positions, and 27 closing their positions.
48% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 27
26% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 73
5% more funds holding
Funds holding: 236 → 248 (+12)
2.58% less ownership
Funds ownership: 97.88% → 95.3% (-2.6%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
15% less capital invested
Capital invested by funds: $3.81B → $3.25B (-$558M)
41% less call options, than puts
Call options by funds: $33.5M | Put options by funds: $56.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$52.3M |
| 2 |
RI
RTW Investments
New York
|
+$48.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$24.9M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$23.8M |
| 5 |
FAM
Fred Alger Management
New York
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$85.1M |
| 2 |
Morgan Stanley
New York
|
-$50.8M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$36.1M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$23.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.8M |
ACAD Hedge Fund Activity: Q3 2023 in Review
248 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2023, worth a combined $3.25B — down 15% from $3.81B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ACAD positions and 27 closed out — a net gain of 13 holders — while 92 added to existing stakes and 73 trimmed.
The largest buyer was Millennium Management, adding an estimated $52.3M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $85.1M sold.
- 248 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2023, up from 236 in Q2 2023.
- Funds reported $3.25B of Acadia Pharmaceuticals stock for Q3 2023, down 15% quarter-over-quarter.
- 40 funds opened new Acadia Pharmaceuticals positions in Q3 2023 and 27 closed out, a net change of +13 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2023 was Millennium Management, an estimated $52.3M added.
- The largest Acadia Pharmaceuticals seller in Q3 2023 was Adage Capital Partners, an estimated $85.1M sold.
Based on aggregated 13F filings for Q3 2023.